Virtu Financial LLC Makes New $662,000 Investment in Illumina, Inc. $ILMN

Virtu Financial LLC purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,046 shares of the life sciences company’s stock, valued at approximately $662,000.

Several other institutional investors have also recently made changes to their positions in the business. JPMorgan Chase & Co. increased its stake in shares of Illumina by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock worth $79,081,000 after purchasing an additional 124,246 shares in the last quarter. Elo Mutual Pension Insurance Co purchased a new stake in Illumina in the third quarter worth about $2,319,000. Capital World Investors increased its position in Illumina by 20.0% in the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after buying an additional 3,331,542 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of Illumina by 2,792.2% in the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after buying an additional 911,843 shares during the period. Finally, Neo Ivy Capital Management bought a new position in shares of Illumina in the third quarter worth about $1,827,000. Institutional investors own 89.42% of the company’s stock.

Insider Activity

In other Illumina news, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the sale, the senior vice president owned 15,056 shares in the company, valued at $2,093,386.24. The trade was a 4.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $150.10, for a total transaction of $225,150.00. Following the transaction, the chief accounting officer directly owned 14,946 shares of the company’s stock, valued at $2,243,394.60. This trade represents a 9.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,003,154 shares of company stock valued at $155,600,208 in the last quarter. Company insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on ILMN. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Wall Street Zen downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a research report on Thursday, May 14th. Finally, JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $125.00 to $185.00 in a research note on Wednesday, June 10th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Illumina currently has an average rating of “Hold” and an average price target of $142.12.

Illumina Stock Performance

NASDAQ:ILMN opened at $161.38 on Tuesday. The stock has a 50-day moving average price of $145.95 and a 200 day moving average price of $136.45. The stock has a market capitalization of $24.42 billion, a P/E ratio of 29.34, a P/E/G ratio of 3.03 and a beta of 1.50. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $177.22. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the company posted $0.97 EPS. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts forecast that Illumina, Inc. will post 5.21 EPS for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.